The SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections

Domenico Mattoscio, Chiara Casadio, Marzia Fumagalli, Mario Sideri, Susanna Chiocca

Research output: Contribution to journalArticle

Abstract

Human papillomaviruses (HPVs) infect stratified epithelium and are the causative agents of cervical cancer, the second most common cause of cancer-related death in women. A critical aspect that still persists in the HPV field is the selection of very sensitive and specific HPV diagnostic assays. Here, we provide evidence that the crucial small ubiquitin-like modifier (SUMO) E2-conjugating enzyme Ubc9 is strongly upregulated in cervical lesions. Ubc9 detection could thus be used in diagnosing and/or monitoring the progression of an HPV oncogenic infection.

Original languageEnglish
Article number534
Journalecancermedicalscience
Volume9
DOIs
Publication statusPublished - Apr 29 2015

    Fingerprint

Keywords

  • Biomarker
  • Cervical cancer
  • HPV
  • HSIL
  • LSIL
  • SUMO
  • Ubc9

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this